13 Nov GUNA LOW DOSE CYTOKINES: A MODERN APPROACH IN RHEUMATOLOGY WITH PROVED EFFICACY AND SAFETY
V. Prokopiev
Intellect Pharma Plus, Bulgaria
Abstract. GUNA Low Dose Medicine uses at first time low dose interleukins, growth factors, neuropeptides and hormones. GUNA Low Dose cytokines are in concentration of pico- and femtograms and they undergo technology called Sequential Kinetic Activation (SKA). Th1 and Th17 subsets should be in balance with Th2 subset. There is a rise of the secreted by Th1 and Th17 inflammatory (immunostimulating) cytokines IL-1, IL-6, TNF-α, IL-17, INF-γ, IL-2, IL-8 and reduction of Тh2 subset in inflammation. In opposite side: there is a rise in Th2 subset with increased IL-4, IL-5, IL-13 in allergy. It should be applied GUNA anti-IL-1 in acute inflammation, GUNA IL-10 in chronic inflammation and GUNA IL-4 for control of autoimmune initiation. The role of IL-1, IL-6, TNF-α in pathogenesis of osteoarthritis, rheumatoid arthritis, osteoporosis is known and proved. Clinical trial shows that GUNA low dose anti-IL-1 and IL-10 are efficient in osteoarthritis of hand and knee. Combination of GUNA anti-inflammatory cytokines and GUNA anti-cytokines results in satisfactory efficacy in maintaining of LDA or remission obtained with bDMARDs in patient with rheumatoid arthritis. Safety is excellent. GUNA low dose IL-10 and GUNA Osteobios will keep bone density in menopausal osteoporosis and GUNA IL-10 will help for successful treatment of fibromialgia. GUNA Low Dose therapy, alone or in combination, supports traditional therapies, helps in subchronic inflammatory condition control. Low dose cytokines could be an alternative in patients with contraindications or adverse events with conventional drugs.
Key words: GUNA Low Dose cytokines, Sequential Kinetic Activation (SKA), osteoarthritis, rheumatoid arthritis, osteoporosis, fibromialgia
For full article see: Rheumatology magazine: 2017: Issue 4
http://rheumatologybg.org/index.php/rheumatology-issues/155-rheumatology-2017-issue4